Equillium to Present at Two Upcoming Investor Conferences
November 08 2022 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that it will participate in fireside chat
presentations at the Stifel Healthcare Conference and the Jefferies
London Healthcare Conference.
Management will provide a high-level overview of the company,
clinical assets, clinical programs and upcoming catalysts and
milestones. Management will also be available for one-on-one
meetings during both conferences.
Conference: Stifel Healthcare Conference Location:
Lotte New York Place Hotel, 4th Floor, Holmes Room II Date:
Tuesday, November 15 Time: 12:00 pm Pacific Time | 3:00 pm
Eastern Time
Conference: Jefferies London Healthcare Conference
Location: Waldorf Hilton, London, Westminster Room, Entresol
Level Date: Thursday, November 17 Time: 12:35 am
Pacific Time | 8:35 am Greenwich Mean Time
Webcast access for both presentations will be available on the
“Events & Presentations” page under the Investor Relations tab
on the Company’s website at
https://www.equilliumbio.com/investors/events-and-presentations/default.aspx.
An archived replay of both conferences will be available for 90
days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. EQ101 is a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15. Equillium expects to begin enrolling patients in
an alopecia areata Phase 2 study of EQ101 in the fourth quarter of
2022. EQ102 is a bi-specific cytokine inhibitor that selectively
targets IL-15 and IL-21. Equillium is currently enrolling patients
in a Phase 1 study of EQ102, including healthy volunteers and
celiac disease patients.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of the Company’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the potential
for any of Equillium’s ongoing or planned clinical studies to show
safety or efficacy, Equillium’s anticipated timing of regulatory
review and feedback, and Equillium’s plans and expected timing for
developing its product candidates and potential benefits of its
product candidates. Risks that contribute to the uncertain nature
of the forward-looking statements include: uncertainties related to
the abilities of the leadership team to perform as expected;
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; the risk that interim
results of a clinical study do not necessarily predict final
results and that one or more of the clinical outcomes may
materially change as patient enrollment continues, following more
comprehensive reviews of the data, and as more patient data become
available; potential delays in the commencement, enrollment and
completion of clinical studies and the reporting of data therefrom;
the risk that studies will not be completed as planned; Equillium’s
plans and product development, including the initiation and
completion of clinical studies and the reporting of data therefrom;
whether the results from clinical studies will validate and support
the safety and efficacy of Equillium’s product candidates; changes
in the competitive landscape; uncertainties related to Equillium’s
capital requirements; and having to use cash in ways or on timing
other than expected and the impact of market volatility on cash
reserves. These and other risks and uncertainties are described
more fully under the caption "Risk Factors" and elsewhere in
Equillium's filings and reports, which may be accessed for free by
visiting EDGAR on the SEC web site at http://www.sec.gov and on the
Company’s website under the heading “Investors.” Investors should
take such risks into account and should not rely on forward-looking
statements when making investment decisions. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Equillium undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005336/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024